SIHUAN PHARMACE risk profile
44 Elevated one input has moved against it
Measured 1 September 2026 from TEL1's filed statements. Recomputed nightly.
44 (Elevated), driven by Cash conversion at 96, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 90 | Acute | Stable | Drawdown from the 52-week high — 60.6% |
| Operating pressure | 1 | Contained | Easing | Input-cost exposure — 0.02 |
| Cash conversion | 96 | Acute | Worsening | Capital spending against operating cash — -8.26x |
| Leverage and coverage | 26 | Normal | Easing | Interest cover — 4.19x |
| Competitive position | 50 | Elevated | Stable | Revenue-growth gap against peers — -15.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.